DEFM14A: Aimfinity Investment Corp. I Eyes Merger with Docter Inc. in $60 Million Deal

Aimfinity Investment Corp. I is seeking shareholder approval for a business combination with Docter Inc., a health monitoring technology company, in a deal valued at $60 million.

Summary

• Aimfinity Investment Corp. I (AIMA) is proposing a business combination with Docter Inc., a Delaware corporation, through a merger agreement.
• The deal involves Aimfinity merging with Aimfinity Investment Merger Sub I (PubCo), followed by Aimfinity Investment Merger Sub II merging with Docter, making Docter a wholly-owned subsidiary of PubCo.
• The aggregate consideration for the acquisition is $60 million, payable to Docter's stockholders in the form of 6,000,000 newly issued PubCo Ordinary Shares valued at $10.00 per share.
• Docter stockholders may also receive up to 2,500,000 additional PubCo Ordinary Shares if PubCo achieves certain sales targets in fiscal years 2025 and 2026.
• Aimfinity shareholders will vote on proposals to approve the reincorporation merger, the acquisition merger, and the PubCo charter.
• A backstop agreement is in place with Family Inheritance Consulting (H.K.) Limited to purchase AIMA Class A Ordinary Shares to ensure PubCo has at least $5,000,001 in net tangible assets at closing.
• Upon consummation, Aimfinity shareholders are expected to own approximately 48.5% and Docter stockholders approximately 51.5% of the issued PubCo Ordinary Shares, assuming no redemptions.
• The AIMA Units, AIMA New Units, and AIMA Class 1 Warrants are currently listed on the Nasdaq Global Market under the symbols AIMAU, AIMABU, and AIMAW, respectively.
• PubCo intends to apply to list the PubCo Ordinary Shares and PubCo Warrants on the Nasdaq Stock Market under the symbols INKS and INKSW, respectively.
• Aimfinity estimates the per-share price at which AIMA Public Shares may be redeemed from cash held in the Trust Account will be approximately $12.08 per share.
• The Extraordinary General Meeting is scheduled for March 27, 2025.

Sentiment

Score: 6

Explanation: The document is largely factual, but the presence of risks and potential dilution tempers the overall sentiment. The backstop agreement provides some reassurance, but the reliance on future sales targets and the potential for redemptions create uncertainty.

Positives

• A backstop agreement is in place to ensure PubCo has a minimum of $5,000,001 in net tangible assets after the merger.
• Docter stockholders could receive an additional 2,500,000 PubCo Ordinary Shares if sales targets are met in 2025 and 2026.
• Aimfinity shareholders may redeem their shares for approximately $12.08 per share.

Negatives

• If any of the existing AIMA Public Shareholders exercise their redemption rights, the anticipated percentage ownership of Aimfinitys existing shareholders will be reduced.
• Investing in PubCo securities involves a high degree of risk.
• Aimfinity shareholders will experience immediate dilution as a consequence of the issuance of PubCo Ordinary Shares as consideration in the Business Combination.
• Having a minority share position may reduce the influence that Aimfinitys current shareholders have on the management of PubCo.

Risks

• Investing in PubCo securities involves a high degree of risk.
• Aimfinity shareholders will experience immediate dilution as a consequence of the issuance of PubCo Ordinary Shares as consideration in the Business Combination.
• Having a minority share position may reduce the influence that Aimfinitys current shareholders have on the management of PubCo.
• The conversion of any working capital loans or extension loans into working capital units or extension units may result in significant dilution to AIMA Public Shares.
• There is no guarantee that a shareholders decision whether to redeem its Public Shares for a pro rata portion of the Trust Account will put such shareholder in a better future economic position.

Future Outlook

PubCo intends to apply to list the PubCo Ordinary Shares and PubCo Warrants on the Nasdaq Stock Market under the symbols INKS and INKSW, respectively, in connection with the closing of the Business Combination. Aimfinity cannot assure you that the PubCo Ordinary Shares and PubCo Warrants will be approved for listing on Nasdaq.

Management Comments

• On behalf of the Aimfinity Board, I thank you for your support and Aimfinity looks forward to the successful consummation of the Business Combination.
• Sincerely, /s/ I-Fa Chang I-Fa ChangChairman of the BoardAimfinity Investment Corp. I March 6, 2025

Industry Context

The announcement relates to the smart home healthcare industry, which is experiencing significant growth and consolidation. The business combination aims to capitalize on the increasing demand for remote health monitoring and personalized healthcare solutions.

Comparison to Industry Standards

• The document mentions comparable public companies in the wearable healthcare monitoring sector, such as Garmin Ltd., DexCom, Inc., iRhythm Technologies, Inc., Vuzix Corporation, and Lifecare AS.
• These companies serve as benchmarks for valuation and performance analysis.
• The average EV/2025E Revenue multiple of such comparable public companies was 10.8x; this multiple was multiplied by the 2025E Revenue of Docter ($6.4M) to obtain an Enterprise value of $68.9M.

Related Party Transactions

• The Sponsor and Aimfinitys officers and directors and their affiliates are entitled to reimbursement of reasonable out-of-pocket expenses incurred by them in connection with certain activities on Aimfinitys behalf, such as identifying and investigating possible business targets and business combinations.
• In order to extend Aimfinitys time to complete a business combination by up to an additional nine months as provided in its Current Charter, Aimfinitys Sponsor or our directors and officers or their designees must deposit the Monthly Extension Payment into the Trust Account for each one-month extension.
• Aimfinitys officers and directors may make loans from time to time to Aimfinity to fund certain capital requirements.
• The Sponsor and its affiliates will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to shareholders rather than liquidate.
• Aimfinitys Chief Financial Officer, Mr. Tian, was the managing director and head of capital market of US Tiger, Aimfinitys business combination advisor and one of the representatives of the underwriters of Aimfinitys IPO.
• Aimfinitys CEO, Mr. Chang, is the manager and one of the members of the Sponsor. He beneficially owns 91.1% of the membership interests of the Sponsor, and may be deemed to beneficially own 1,542,500 AIMA Class B Ordinary Shares.
• Aimfinitys CFO, Mr. Tian, is also a member of the Sponsor. He beneficially owns 5.9% of the membership interests of the Sponsor, and may be deemed to beneficially own 100,000 AIMA Class B Ordinary Shares.

Stakeholder Impact

• The Business Combination will impact Aimfinity shareholders, Docter stockholders, employees, and potentially customers.
• Aimfinity shareholders will become PubCo shareholders and may experience dilution.
• Docter stockholders will receive PubCo Ordinary Shares and may be entitled to earnout shares.
• Employees of both companies may be affected by the integration process.
• Customers may see changes in the products and services offered by the combined company.

Next Steps

• Aimfinity shareholders will vote on the Reincorporation Merger Proposal, the Acquisition Merger Proposal, the PubCo Charter Proposal, and the Adjournment Proposal at the Extraordinary General Meeting on March 27, 2025.
• If the proposals are approved, the Business Combination is expected to close as soon as practicable following the satisfaction of the closing conditions.

Key Dates

Keywords

Business Combination, Merger, Docter Inc., Aimfinity, PubCo, Shareholders, Redemption, Warrants, Ordinary Shares, Merger Agreement